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1. Introduction 
Like several other peptides, vasoactive intestinal 
polypeptide (VIP) occurs in gastrointestinal and ner- 
vous tissues [I]. In the central nervous system, VIP 
has a discrete distribution, being most abundant in 
cerebral cortex and hypothalamus, including, in hu- 
man brain, the median eminence [2,3]. VIP is also 
concentrated in nerve endings from which it can be 
released on depolarization [2,4]. These and other 
data [5] favour a neurotransmitter or neuromodu- 
lator role for the peptide. 
Recently, immunoreactive VIP was found in portal 
hypophyseal blood in concentrations 19-times those 
in peripheral blood [6], suggesting release of the pep- 
tide from the hypothalamus and raising the possibil- 
ity that it may control some aspects of pituitary func- 
tion. To examine the latter possibility we investigated 
the ability of VIP to stimulate adenylate cyclase 
activity in the rat pituitary, since activation of this 
enzyme correlates with hormonal secretion in this 
gland [7]. 
2. Materials and methods 
VIP was the natural porcine polypeptide prepared 
in the laboratory of Professor V. Mutt, Karolinska 
Institutet, Stockholm. Synthetic fragments VIP6__2s 
and VIP14_-28 were prepared by Professor M. 
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Bodanszky , Cleveland, OH. 
8-[14C]ATP and 8-[‘HIcAMP were from The 
Radiochemical Center, Amersham. ATP, CAMP, nore- 
pinephrine, haloperidol, D,L-propranolol, creatine 
phosphate and creatine phosphokinase were pur- 
chased from Sigma, St Louis, MO. [Arg’]-vasopressin 
was obtained from Sandoz, AG, Base1 and GTP from 
Boehringer-Mannheim Gmbh. 
2.1. Preparation of homogenates 
Male rats (Sprague-Dawley 1 SO-200 g) were killed 
by decapitation; pituitaries were rapidly dissected, 
washed in icecold Tris-maleate buffer (50 mM, 
pH 7.4) containing 0.33 mM EGTA, and homoge- 
nized in the same medium (1:60, w/v). The homoge- 
nate was either used as such (2-3 mg protein/ml) or 
centrifuged at 12 000 X g at 0°C for 1.5 min. The 
pellet was resuspended in Tris-maleate (50 mM, 
pH 7.4) to give 1 Z-2 mg protein/ml. 
2.2. Adenylate cyclase assay 
The adenylate cyclase assay was performed essen- 
tially as in [8]. Incubation was carried out at 30°C 
for 5 min, unless stated otherwise. The standard assay 
mixture contained Tris-maleate buffer (50 mM, pH 
7.4); 8-[14C]ATP (0.15 mM, 50 dpm/pmol); 8-[3H]- 
CAMP (0.15 mM, 300 dpm/nmol); creatine phosphate 
(7 mM), creatine phosphokinase (6.2 U/ml); MgS04 
(5 mM); EGTA (0.1 mM, added with the homoge- 
nate); and substances to be tested, dissolved in the 
Tris-maleate buffer. Isolation and detection of 
8-[3H,‘4C]cAMP was performed according to [9]. 
Protein was assayed according to [ lo]. 
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3. Results 
VIP activated the adenylate cyclase in homoge- 
nates of rat pituitary in a concentration-dependent 
fashion, with an app. K, = 2 X IO-’ M (fig.1). 
The accumulation of CAMP, at the maximally 
effective concentration (10m6 M) of the peptide, was 
Fig.1. VIP-induced, concentration-dependent activation of 
adenylate cyclase in homogenate of pituitary gland. Each 
point is the mean of 3-6 values. 
minutes 
Fig.2. Time-course of basal (open circles) and VIP-stimulated 
(closed circles) cyclic AMP accumulation in homogenate of 
pituitary gland. Each point is the mean of 3-6 values. 
a linear function of time, over the period of observa- 
tion (fig.2), and was not influenced by bacitracin, an 
inhibitor of peptidases (data not shown). 
Th? magnitude of VIP (1 Oe6 M)-induced stimula- 
tion of adenylate cyclase was comparable to that ob- 
tained by NaF (1 Om2 M) and higher (2-fold) than that 
elicited by PGE2 (2 X 10m6 M) (table 1). Other pep- 
tides, [A$] -vasopressin (1 0e6 M), and the synthetic 
VIP fragments, VIP6_2s and VIP14_28 (5 X lo-’ M 
in each case), were completely devoid of stimulatory 
activity (table 1). Other experiments (not reported 
here) showed that the VIP-induced stimulation of 
adenylate cyclase was unaffected by the addition of 
the VIP synthetic fragments (both at 5 X lo-’ M), or 
propranolol, a p-adrenergic antagonist ( 10m6 M). In 
addition,neither dopamine (1O-7-1O-5 M) nor halo- 
peridol, a dopamine-receptor blocker (10e6 M) modi- 
fied the extent of VIP activation. 
Both eCE2 and norepinephrine promoted the for- 
mation of CAMP in pituitary homogenates, being 
maximally effective at 10m5 M; addition of VIP 
( 10d6 M) to the incubation medium increased the for- 
mation of CAMP elicited by either agent (fig.3). On 
the other hand, VIP had no influence on the pituitary 
cyclase already exposed to the maximally effective 
concentration of NaF (1 O-2 M) (fig.3). 
To test the influence of Ca2+ and GTP on adenyl- 
ate cyclase, these factors were added to resuspensions 
of particulate fractions obtained by centrifuging 
pituitary homogenates (12 000 X g for 15 min). Ca2+ 
at < 10e6 M increased moderately (2-fold) the basal 
Table 1 
Rat pituitary adenylate cyclase: Stimulation by 
various agents 
Additions pmol cAMP/mg Stimu- 
protein X min lation 
(mean f SD, (-fold) 
n = 3-6) 
None 29.6 + 3.3 _ 
VIP 1O-6 M 120.2 + 8.0 4.06 
PGE, 2 X 1O-6 M 63.0 f 6.8 2.13 
NaF lo-* M 131.1 r 6.6 4.43 
[Arg*]-vasopressin 1O-6 M 26.9 + 4.3 0.89 
VIP,-, 8 5 X 1O-5 M 28.1 k 4.4 0.95 
VIP, 4-2 8 5 x 10-5M 27.2 + 2.8 0.92 
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cyclase activity; higher concentrations of this ion 
(1 O-‘-l O-’ M) resulted in marked inhibition of basal 
adenylate cyclase activity and complete abolition of 
VIP stimulation (data not shown). GTP 
( 10m7 -lo-’ M) stimulated the rat pituitary cyclase 
and strongly enhanced the stimulant effect of VIP on 
this enzyme (fig.4). 
q -“‘P 8. 
PGE 2 NE NaF 
10-J M IO-J M 10-z M 
Fig.3. Effect of PGE,, norepinephrine (NE) and NaF on 
basal (open bars) and VIP-stimulated (hatched bars) adenyl- 
ate cyclase in homogenate of pituitary gland. Values are 
means of 3 determinations, ? SD. 
Fig.4. Effect of GTP on basal (open circles) and VIP-stimu- 
lated (closed circles) adenylate cyclase in particulate fraction 
(pellet at 12 000 X g) of pituitary gland. Each point is the 
mean of 3-6 values. 
4. Discussion 
Earlier studies established the ability of VIP to 
stimulate adenylate cyclase activity in homogenates 
of brain and several other organs of rat and other 
species [8,1 l-161. The present results show that the 
peptide also activates this enzyme in rat pituitary. 
This activation seems to occur via a specific receptor, 
distinct from that responsible for the action of PGEz 
or norepinephrine, since the effects of either of these 
agents with VIP were additive (fig.3). Further, the 
P-blocker, propranolol, was without effect on this 
VIP action, indicating that the VIP receptor is dis- 
tinct from the P-receptor in this organ, as it is in other 
organs and tissues [ 171. 
Dopamine has been demonstrated to have an 
inhibitory action on prolactin release [l&19], and on 
the adenylate cyclase from human pituitary adenoma 
[20]. It was tempting, therefore, to speculate that 
VIP and dopamine may act through the same re- 
ceptor (to cause opposite effects). This does not ap- 
pear to be the case, however, since neither dopamine 
nor a dopamine receptor-blocker (haloperidol) af- 
fected VIP-stimulation of adenylate cyclase. 
In agreement with work on rat brain homogenates 
[8], the partial sequences of VIP, VIP6_-28, and 
VIP14_-28, were inactive as agonists or antagonists of 
VIP. These data suggest hat the N-terminal 5 amino 
acids of the molecular sequence are required for bind- 
ing or for recognition by VIP receptors in this prepa- 
ration. Recent studies on [1251]VIP binding to brain 
membranes have reached similar conclusions 1211. 
As observed in similar studies on rat cerebral cor- 
tex 181, Ca2+, which had a biphasic effect on basal 
pituitary adenylate cyclase, completely abolished VIP 
stimulation of this enzyme. Conversely, this action of 
VIP was markedly potentiated by GTP, in a manner 
consistent with the controlling influence of this com- 
pound on cyclase stimulation by hormones and neu- 
rotransmitters [22]. 
VIP stimulated the pituitary adenylate cyclase in a 
concentration range (1 Oe7 M) comparable to that ob- 
served for other hypothalamic peptides [23]. Other 
tissues, particularly enterocytes, respond at lower 
concentrations of VIP [24]. The reasons for the lower 
sensitivity of the pituitary enzyme are not clear, but 
could be related to different sensitivities of different 
cell types represented in the pituitary homogenates. 
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VIP has been reported to stimulate the secretion 
of prolactin from the rat pituitary [25-271. In two 
of these reports, the VIP effect was obtained only in 
vivo, while in the third a direct action on the pitui- 
tary was observed. Strong evidence points to a close 
relationship between the accumulation of CAMP elic- 
ited by neural peptides and the secretion of pituitary 
hormones. In the instances in which the activation of 
the enzyme and the hormonal secretion were mea- 
sured simultaneously the correlation has been excel- 
lent [7]. The secretion of prolactin is tonicalty inhib- 
ited by the activity of the tuberoinfundibular dopa- 
minergic neurons, but is probably controlled also by 
positive hypothalamic influences [28]. Thus, prolac- 
tin-releasing activity has been detected in the median 
eminence of the rat hypothalamus 1291. The presence 
of VIP i~unoreactivity and ~lmunofluorescenc~ in 
these areas, together with the stimulation of pituitary 
adenylate cyclase reported here, makes this peptide a 
possible candidate for the postulated hypothalamic 
positive influence on prolactin secretion. 
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